TAIPEI, TAIWAN – July 22, 2025 – Marker X CO., LTD., a recognized leader in biomarker development and proteomics analysis, today announced the official launch of MyeloTrak™. This groundbreaking non-invasive diagnostic for Multiple Myeloma (MM) relapse monitoring requires no bone marrow aspiration, offering unprecedented sensitivity and high specificity to hematologists and oncology professionals. MyeloTrak™ aims to fundamentally transform MM patient management and achieve Early Relapse Control, ushering in a new era of precision oncology. MarkerX is showcasing this transformative cancer diagnostic at the prestigious BIO Asia 2025 in Taipei.

MyeloTrak™: Enhanced Patient Experience through Non-invasive Monitoring

 A cornerstone of MyeloTrak™'s superiority is its non-invasive nature, requiring only 5 mL of peripheral blood, eliminating the need for painful and invasive bone marrow aspiration. This dramatically enhances patient comfort, reduces potential complications and anxiety, and critically boosts long-term monitoring adherence. Its non-invasive aspect supports high-frequency follow-up (e.g., every 2-4 weeks), aligning closely with dynamic clinical needs. This revolutionary approach directly improves the patient experience in MM surveillance, promoting consistent early detection.

MyeloTrak™ Technical Advantages: Precision Beyond Limits 

MyeloTrak™ stands at the forefront of liquid biopsy and cancer diagnostics with its formidable analytical power. It boasts thousands-fold greater sensitivity for M-protein detection compared to traditional methods (e.g., electrophoresis, EP). This allows for the precise capture of even minimal residual disease (MRD), enabling true early relapse warning previously unattainable. Coupled with its high specificity, MyeloTrak™ leverages advanced mass spectrometry to identify diverse MM subtypes and precisely track unique M-protein sequences, providing unparalleled personalized insights into disease progression.

MyeloTrak™ Technical Advantages: Robustness & Self-Developed Big Data Model 

What truly sets MyeloTrak™ apart in the liquid biopsy space is its robust immunity to therapeutic antibody interference. Unlike conventional assays that can yield compromised data due to monoclonal antibody treatments (such as Darzalex), MyeloTrak™'s patent-pending analytical workflow (TW) and proprietary self-developed big data model are meticulously designed to ensure data integrity. By selectively enriching target M-proteins and utilizing advanced LC-MS/MS for unique peptide identification, MyeloTrak™ delivers dependable, quantified MRD indices and clear trend charts. This empowers clinicians to make highly informed precision medicine decisions based on accurate, undisturbed data, even during active therapy.

Transforming MM Care: A Significant Market Opportunity 

MyeloTrak™ is set to redefine global MM care standards. By enabling unprecedented early relapse visibility, it empowers hematologists to implement proactive management strategies, potentially prolonging remission and improving patient survival. Crucially, the US FDA and European EMA publicly affirm MRD negativity as an early endpoint in MM clinical trials, poised to accelerate global drug development and expand precision medicine's clinical application. As a leader in non-invasive, blood-based MRD detection, MyeloTrak™ represents a significant leap, meeting the urgent market need for advanced cancer management tools and enhanced patient quality of life, making it a prime biotech investment.

Our Vision: Pioneering Health Investment 

MarkerX leads the crucial shift towards ultra-early diagnosis, firmly believing preventive medicine must intervene much earlier in pre-disease pathways. We envision a future where healthcare funding fundamentally moves from mere disease remediation to health investment. Our blueprint aims to foster a collaborative health investment platform, uniting national health insurance, commercial insurance providers, government, and private data initiatives. This collective effort will channel resources towards teams truly dedicated to preventing disease inception, transcending the current payout-based healthcare system.

Driving Global Healthcare Innovation 

Beyond MyeloTrak™, MarkerX is proud to have already launched AI Proteomics Early Cancer Screening, demonstrating our broad capabilities in early cancer detection. We are actively planning cross-ethnic platform validation to ensure our technologies serve diverse global populations, including the US market. At the BIO Asia Convention, MarkerX is actively seeking global strategic partnerships, clinical collaborations with leading hematology centers, investment opportunities to scale our diagnostic pipeline, and IVD regulatory strategy support for market expansion. We are committed to advancing healthcare innovation worldwide.

About Marker X CO., LTD.

 Marker X CO., LTD. is a leading Taiwan biotech company specializing in novel biomarker development and proteomics analysis. Driven by a commitment to lead in proteomic diagnostics, the company leverages cutting-edge technology to translate innovative disease-related biomarkers into clinically actionable diagnostic applications, contributing substantially to global health.

Contact:

 [Debby Chen / CEO Office]
Email: support@marker-x.com
Phone: +886-2-77302526
Website: www.marker-x.com